EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The role of aryl hydrocarbon receptor agonists in the management of inflammatory skin diseases: An expert consensus panel

Lauren DeBusk, Brooke Bartley, April W Armstrong, Christopher G Bunick, James Del Rosso, Seemal R Desai, Lawrence F Eichenfield, Boni E Elewski, Alexandra K Golant, Naiem Issa, Linda Stein Gold, Lisa Swanson und 4 weitere

Dermatology Online Journal · 06.07.2026 · 32 (3)

DOI: 10.25251/ha2gbq97 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Dermatology Online Journal, online erschienen am 06.07.2026. Verfasst von Lauren DeBusk und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, TX, USA. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Receptors, Aryl Hydrocarbon, Psoriasis. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Inflammatory skin diseases, including psoriasis and atopic dermatitis, require long-term management strategies that balance efficacy with safety. The 2025 American Academy of Dermatology guidelines encourage the judicious application of topical corticosteroids when their use is deemed necessary and for short durations of therapy. Recent availability of newer non-steroidal topical therapies that are effective and safe, including for prolonged durations and on sensitive skin sites, has prompted a need for evidence-based guidance for clinicians in real-world practice. Tapinarof, a first-in-class, nonsteroidal aryl hydrocarbon receptor (AhR) agonist, was approved by the FDA for the treatment of plaque psoriasis in adults and atopic dermatitis in patients aged 2 years and older in 2022 and 2025, respectively; however, its optimal place in therapy remains to be established.

Objective

To develop expert consensus statements on the role of AhR agonists in the management of inflammatory skin diseases.

Methods

A literature search produced thirty-one articles meeting inclusion criteria that were independently reviewed by an eleven-member expert panel that convened on January 19, 2026. A modified Delphi process was used to develop nine consensus statements. Consensus Recommendations/Key Findings: AhR agonists represent a distinct therapeutic class with a unique multimodal mechanism involving immune modulation across Th1/Th2/Th17/Th22 pathways, skin barrier normalization, and antioxidant activity; tapinarof demonstrates a favorable safety profile with no restrictions on anatomic site, body surface area, or duration of use; tapinarof may be used concomitantly with systemic therapies; tapinarof is appropriate as both initial and long-term therapy for psoriasis in adults and atopic dermatitis in patients aged 2 years and older; and non-steroidal topical therapies are preferred for chronic inflammatory skin diseases, particularly on the face and intertriginous areas.

Conclusion

AhR agonist therapy offers a clinically meaningful, advanced non-steroidal option that addresses key limitations of traditional topical therapies in inflammatory skin disease management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicReceptors, Aryl HydrocarbonPsoriasisHumansResorcinolsStilbenes

Stichwörter der Autor:innen

ADORINGPSOARINGatopic dermatitisclinical care guidelinespsoriasissteroid sparingtapinaroftopical therapy

Substanzen

Receptors, Aryl HydrocarbontapinarofResorcinolsStilbenes

Autor:innen und Institutionen

  • Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
  • Division of Dermatology, Department of Medicine, University of California Los Angeles David Geffen School of Medicine, Los Angeles, CA, USA.
  • Department of Dermatology, Program in Translational Biomedicine, Institute for Global Health, Yale University School of Medicine, New Haven, CT, USA.
  • JDR Dermatology Research, Las Vegas, NV, USA.
  • Innovative Dermatology, Plano, TX, USA.
  • Departments of Dermatology and Pediatrics, University of California San Diego, School of Medicine, La Jolla, CA, USA.

Zitieren

APA

DeBusk, L., Bartley, B., Armstrong, A. W., Bunick, C. G., Del Rosso, J., Desai, S. R., Eichenfield, L. F., Elewski, B. E., Golant, A. K., Issa, N., Stein Gold, L., Swanson, L., Bohman, M. H., Rosenberg, A., Rigel, D., & Lebwohl, M. (2026). The role of aryl hydrocarbon receptor agonists in the management of inflammatory skin diseases: An expert consensus panel. Dermatology Online Journal, 32(3). https://doi.org/10.25251/ha2gbq97

Vancouver

DeBusk L, Bartley B, Armstrong AW, Bunick CG, Del Rosso J, Desai SR, et al. The role of aryl hydrocarbon receptor agonists in the management of inflammatory skin diseases: An expert consensus panel. Dermatology Online Journal. 2026;32(3). doi:10.25251/ha2gbq97

BibTeX
@article{DeBusk2026,
  author = {DeBusk, Lauren and Bartley, Brooke and Armstrong, April W and Bunick, Christopher G and Del Rosso, James and Desai, Seemal R and Eichenfield, Lawrence F and Elewski, Boni E and Golant, Alexandra K and Issa, Naiem and Stein Gold, Linda and Swanson, Lisa and Bohman, M Hunter and Rosenberg, Angela and Rigel, Darrell and Lebwohl, Mark},
  title = {The role of aryl hydrocarbon receptor agonists in the management of inflammatory skin diseases: An expert consensus panel},
  journal = {Dermatology Online Journal},
  year = {2026},
  volume = {32},
  number = {3},
  doi = {10.25251/ha2gbq97}
}
Kostenlos starten →